NEPC, an aggressive subtype evolved from CRPC, is typically resistant to nearly all current therapies.[42, 43] We found that SFT2D2‐TBX19 was gradually increased from castration‐resistant prostate cancer cell lines PC3, C4‐2, DU145, 22RV1 to neuroendocrine prostate cancer cell lines NCI‐H660. This evidence concerns the gene SFT2D2 and prostate cancer.